| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | -247,9 k € | +51.8% | -513,9 k € | -539.9% | -80,3 k € | -202.4% | 78,4 k € | -32.6% | 116,3 k € | -42.6% | 202,6 k € | +112.1% | 95,5 k € | -30.0% | 136,5 k € | +619.0% | -26,3 k € | |
| EBITDA | -248,1 k € | +52.1% | -517,7 k € | -252.8% | -146,7 k € | -2579.7% | 5,9 k € | -86.5% | 44,0 k € | -78.2% | 201,8 k € | +189.8% | -224,7 k € | -33.0% | -168,9 k € | -21.1% | -139,5 k € | |
| Operating profit | -549,1 k € | +25.9% | -741,2 k € | -62.7% | -455,6 k € | +4.8% | -478,4 k € | +8.4% | -522,4 k € | -60.8% | -324,9 k € | +77.7% | -1,5 M € | +29.5% | -2,1 M € | -90.4% | -1,1 M € | |
| Profit/loss | -629,3 k € | +2.6% | -645,8 k € | -4.8% | -616,3 k € | -22.9% | -501,4 k € | -80.8% | -277,3 k € | +20.8% | -350,1 k € | -183.1% | 421,5 k € | +140.7% | -1,0 M € | -79.6% | -576,1 k € | |
| Equity | -841,8 k € | +27.7% | -1,2 M € | +17.6% | -1,4 M € | -77.2% | -798,2 k € | -169.0% | -296,8 k € | -1420.7% | -19,5 k € | -105.9% | 330,6 k € | +463.6% | -90,9 k € | -109.6% | 944,1 k € | |
| Total assets | 941,2 k € | -22.6% | 1,2 M € | +240.6% | 357,2 k € | -65.6% | 1,0 M € | -35.1% | 1,6 M € | -9.0% | 1,8 M € | -33.3% | 2,6 M € | +47.9% | 1,8 M € | +32.5% | 1,3 M € | |
| Cash | 158,3 k € | -71.3% | 551,6 k € | +634.3% | 75,1 k € | -85.8% | 527,7 k € | -18.5% | 647,6 k € | +122.5% | 291,0 k € | +528.0% | 46,3 k € | -78.8% | 218,2 k € | +83.9% | 118,7 k € | |
| Debts | 1,8 M € | -16.0% | 2,1 M € | +19.8% | 1,8 M € | -3.6% | 1,8 M € | -3.2% | 1,9 M € | +6.7% | 1,8 M € | -22.9% | 2,3 M € | +23.1% | 1,9 M € | +366.8% | 401,5 k € | |
| Staff | — | — | 66 197,7 | 0,3 | — | — | 5,8 | 4,6 | 1,8 | |||||||||
Public limited company · Liège · incorporated on 24/02/2017
Public limited company loss-making in the latest fiscal year. Cash position declining (-71.3%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
CONVERT PHARMACEUTICALS is a Public limited company incorporated in 2017. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Liège.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette